This study indicates that IL17-related genetic polymorphisms and metabolic characteristics significantly affect liver fibrosis progression in MASLD patients, with the IL17A-G197A gene polymorphism identified as an independent multivariate predictor of fibrosis progression. Here, IL17A is linked to Hepatic fibrosis.